Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Method to Halt the Advance of Liver Cancer Study suggests that drugs targeting the lymphotoxin-beta receptor may improve liver cancer treatment in 'Newswise', Sanford Burnham Prebys Medical Discovery Institute, 23-Jul-2015

Excerpts:
"For some time we have known about the interconnection between the receptor, inflammation—including inflammation caused by hepatitis—and liver cancer. Now, we have demonstrated how the receptor’s signals create an environment that accelerates oncogenic activity and tumor growth,”"

"The LTßR, originally discovered by Ware, is best known for controlling the development of lymphoid organs, supporting the body’s immune response to pathogens, and regulating inflammation. His work has led to the understanding that blocking the activity of the receptor inhibits inflammation. This approach is currently studied as a treatment for chronic inflammatory diseases, including Sjögren’s syndrome."

"Importantly, the research team found that LTßR levels were elevated in human liver cancer cell lines, reflecting the need for enhanced receptor activity to maintain oncogene activity. Similarly, higher levels of the receptor correlated with poor survival in patients with intrahepatic cholangiocarcinoma, the second most common type of liver tumor."

Article at:
http://www.newswise.com/articles/researchers-find-new-method-to-halt-the-advance-of-liver-cancer